D-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology

Danilo De Gregorio, Stefano Comai, Luca Posa, Gabriella Gobbi

Research output: Contribution to journalReview article

Abstract

D-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles’ reference lists for preclinical studies regarding the mechanism of action involved in the psychotic-like effects induced by LSD. LSD’s mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D2, Trace Amine Associate receptor 1 (TAAR1) and 5-HT2A. More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD’s effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR1 receptors.
Original languageEnglish
Article number1953
Pages (from-to)-
JournalInternational Journal of Molecular Sciences
Volume17
Issue number11
DOIs
Publication statusPublished - Nov 23 2016

Fingerprint

psychoses
pharmacology
Lysergic Acid Diethylamide
Psychotic Disorders
Pharmacology
acids
Acids
Amines
amines
drugs
dosage
dopamine
Serotonin 5-HT1 Receptor Agonists
Receptor, Serotonin, 5-HT2A
lists
Ventral Tegmental Area
PubMed
Synaptic Transmission
Antipsychotic Agents
Dopamine

Keywords

  • Atypical antipsychotics
  • Dopamine
  • Hallucinogens
  • LSD
  • Psychosis
  • Serotonin
  • TAAR

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Computer Science Applications
  • Spectroscopy
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Cite this

D-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology. / De Gregorio, Danilo; Comai, Stefano; Posa, Luca; Gobbi, Gabriella.

In: International Journal of Molecular Sciences, Vol. 17, No. 11, 1953, 23.11.2016, p. -.

Research output: Contribution to journalReview article

De Gregorio, Danilo ; Comai, Stefano ; Posa, Luca ; Gobbi, Gabriella. / D-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology. In: International Journal of Molecular Sciences. 2016 ; Vol. 17, No. 11. pp. -.
@article{9084c5142bc340c7a47f8044928503ea,
title = "D-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology",
abstract = "D-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles’ reference lists for preclinical studies regarding the mechanism of action involved in the psychotic-like effects induced by LSD. LSD’s mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D2, Trace Amine Associate receptor 1 (TAAR1) and 5-HT2A. More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD’s effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR1 receptors.",
keywords = "Atypical antipsychotics, Dopamine, Hallucinogens, LSD, Psychosis, Serotonin, TAAR",
author = "{De Gregorio}, Danilo and Stefano Comai and Luca Posa and Gabriella Gobbi",
year = "2016",
month = "11",
day = "23",
doi = "10.3390/ijms17111953",
language = "English",
volume = "17",
pages = "--",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "11",

}

TY - JOUR

T1 - D-Lysergic Acid Diethylamide (LSD) as a model of psychosis: Mechanism of action and pharmacology

AU - De Gregorio, Danilo

AU - Comai, Stefano

AU - Posa, Luca

AU - Gobbi, Gabriella

PY - 2016/11/23

Y1 - 2016/11/23

N2 - D-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles’ reference lists for preclinical studies regarding the mechanism of action involved in the psychotic-like effects induced by LSD. LSD’s mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D2, Trace Amine Associate receptor 1 (TAAR1) and 5-HT2A. More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD’s effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR1 receptors.

AB - D-Lysergic Acid Diethylamide (LSD) is known for its hallucinogenic properties and psychotic-like symptoms, especially at high doses. It is indeed used as a pharmacological model of psychosis in preclinical research. The goal of this review was to understand the mechanism of action of psychotic-like effects of LSD. We searched Pubmed, Web of Science, Scopus, Google Scholar and articles’ reference lists for preclinical studies regarding the mechanism of action involved in the psychotic-like effects induced by LSD. LSD’s mechanism of action is pleiotropic, primarily mediated by the serotonergic system in the Dorsal Raphe, binding the 5-HT2A receptor as a partial agonist and 5-HT1A as an agonist. LSD also modulates the Ventral Tegmental Area, at higher doses, by stimulating dopamine D2, Trace Amine Associate receptor 1 (TAAR1) and 5-HT2A. More studies clarifying the mechanism of action of the psychotic-like symptoms or psychosis induced by LSD in humans are needed. LSD’s effects are mediated by a pleiotropic mechanism involving serotonergic, dopaminergic, and glutamatergic neurotransmission. Thus, the LSD-induced psychosis is a useful model to test the therapeutic efficacy of potential novel antipsychotic drugs, particularly drugs with dual serotonergic and dopaminergic (DA) mechanism or acting on TAAR1 receptors.

KW - Atypical antipsychotics

KW - Dopamine

KW - Hallucinogens

KW - LSD

KW - Psychosis

KW - Serotonin

KW - TAAR

UR - http://www.scopus.com/inward/record.url?scp=84997261239&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997261239&partnerID=8YFLogxK

U2 - 10.3390/ijms17111953

DO - 10.3390/ijms17111953

M3 - Review article

VL - 17

SP - -

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 11

M1 - 1953

ER -